Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: glatiramer acetate 20 mg Clear all

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: natalizumab, interferon beta 1-a, methylprednisolone, IV placebo, glatiramer acetate; Drug · Other
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 20
States / cities: Cullman, Alabama • San Francisco, California • Fort Collins, Colorado + 15 more

Conditions: Autoimmune Diseases, Multiple Sclerosis
Interventions: Glatiramer acetate, Albuterol, Albuterol placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: BG00002 (natalizumab), interferon beta-1a, glatiramer acetate; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 19
States / cities: Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 16 more

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Glatiramer Acetate, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 25
States / cities: Cullman, Alabama • Fresno, California • La Jolla, California + 17 more

Conditions: Multiple Sclerosis
Interventions: Betaseron, Copaxone; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years to 55 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Relapse-Remitting Multiple Sclerosis
Interventions: glatiramer acetate 20 mg, glatiramer acetate 40 mg; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 20
States / cities: La Jolla, California • Oceanside, California • Atlanta, Georgia + 17 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046), Copaxone; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 2,244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 57
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 52 more

Conditions: Multiple Sclerosis
Interventions: Glatiramer Acetate (GTR), Glatiramer Acetate (Copaxone®), Placebo; Drug
Lead sponsor: Synthon BV; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 794 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 7
States / cities: Irvine, California • Port Charlotte, Florida • Sunrise, Florida + 4 more

Conditions: Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions: fingolimod, glatiramer acetate; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,064 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 101
States / cities: Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 88 more

Conditions: Multiple Sclerosis
Interventions: Copaxone®; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 861 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 15
States / cities: Cullman, Alabama • Carmichael, California • Atlanta, Georgia + 11 more

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Glatiramer acetate, (Copaxone®), IFN-β-1a, (Avonex®); Drug
Lead sponsor: Neurognostics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: Los Angeles, California • Seattle, Washington • Madison, Wisconsin + 1 more

Conditions: Multiple Sclerosis
Interventions: Glatiramer acetate; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 55 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: GA 20 mg/mL, GA 40 mg/mL; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 35
States / cities: Cullman, Alabama • Gilbert, Arizona • Phoenix, Arizona + 31 more

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Plovamer acetate 0.5 milligram (mg), Copaxone 20 mg, Plovamer acetate 3 mg, Plovamer acetate 10 mg, Plovamer acetate 20 mg; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 35
States / cities: Redding, California • San Diego, California • Fairfield, Connecticut + 30 more

Conditions: Relapsing Multiple Sclerosis (RMS)
Interventions: Ofatumumab, mRNA COVID-19 vaccine, interferon or glatiramer acetate; Drug · Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 7
States / cities: Phoenix, Arizona • Hollywood, Florida • Wellesley, Massachusetts + 4 more

Conditions: Multiple Sclerosis
Interventions: Rituximab, Glatiramer Acetate, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 55 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Cyclophosphamide/Glatiramer acetate; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Glatiramer acetate; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2018
U.S. locations: 11
States / cities: Los Angeles, California • New Haven, Connecticut • Baltimore, Maryland + 7 more

Conditions: Multiple Sclerosis, Low Bone Density
Interventions: Copaxone, Interferon-beta 1a, Interferon-beta 1b; Drug
Lead sponsor: Nancy Hammond, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 2
States / cities: Kansas City, Kansas

Conditions: Relapsing-remitting Multiple Sclerosis
Interventions: Rebif®, Copaxone®; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 764 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: BG00012, Placebo, Glatiramer Acetate; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 72
States / cities: Birmingham, Alabama • Cullman, Alabama • Huntsville, Alabama + 69 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 47
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more

Search by objective public record fields.

Treatment Interruption of Natalizumab

Treatment of Multiple Sclerosis With Copaxone and Albuterol

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis

An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI

A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose

BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients

Efficacy and Safety of GTR in Comparison to Copaxone®

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®

An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis

Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis

Safety and Tolerability of Glatiramer Acetate

Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)

A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate

High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis

Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness

Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis

Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial